• 1
    Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974; 33: 1927.
  • 2
    Blackledge G, van Oosterom A, Mouridsen H, et al. Doxorubicin in relapsed soft tissue sarcoma: justification of a phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer. 1990; 26: 139141.
  • 3
    Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable soft tissue sarcoma. J Clin Oncol. 1989; 7: 126.
  • 4
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 5
    Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13: 15371545.
  • 6
    Okuno SH, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced soft tissue sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003; 97: 19691973.
  • 7
    Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft-tissue sarcoma or bone sarcoma resistant to standard chemotherapy: A phase 2 study. Cancer Chemother Pharmacol. 2000; 43: 177181.
  • 8
    Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft-tissue sarcomas. Anticancer Drugs. 2000; 11: 325329.
  • 9
    Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 34833489.
  • 10
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcomas: results of a phase II study. J Clin Oncol. 2002; 20: 28242831.
  • 11
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1991; 9: 419498.
  • 12
    Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992; 10: 406413.
  • 13
    Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21: 34023408
  • 14
    Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201) [abstract]. J Clin Oncol (Meeting Abstracts). 2006; 24: LBA4004.
  • 15
    Fidias P, Demetri G, Harmon DC. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/DANA Farber/Partner's Cancer Care Study [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 513a.
  • 16
    Hirsh V, Langleben A, Ayoub J, Cormier Y, Pintos J, Iglesias JL. Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial. Cancer. 2001; 92: 830835.
  • 17
    Kosmas C, Tsavaris N, Panopoulos C, et al. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane + platinum-based regimens. Eur J Cancer. 2001; 37: 972978.
  • 18
    Nicolaides C, Dimopoulos M, Samantas E, et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2000; 11: 873875.
  • 19
    Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol. 2002; 20: 3741.
  • 20
    Gennatas C, Michalaki V, Mouratidou D, et al. Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. Anticancer Res. 2006; 26(1B): 549552.
  • 21
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 22
    Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002; 38: 543549.
  • 23
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 24
    Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 1985; 41: 741744.
  • 25
    Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004; 22: 17061712.
  • 26
    Hensley ML, Anderson S, Soslow C, et al. Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial [abstract]. J Clin Oncol (Meeting Abstracts). 2004; 22: 9010.
  • 27
    Maki RG, Hensley ML, Wathan JK, et al. A SARC multicenter phase III study of gemcitabine (G) vs gemcitabine and docetaxel (G + D) in patients with metastatic soft tissue sarcoma (STS) [abstract]. J Clin Oncol (Meeting Abstracts). 2006; 24: 9514.